Clinical Trials on Moderate and Severe RheumatoId Arthritis

Total 15029 results

RemeGen Co., Ltd.

Terminated

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis

China
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Moderate to Severe Rheumatoid Arthritis (Auriel-RA)

Moderate to Severe Rheumatoid Arthritis

Bulgaria, United Kingdom, Hungary, Czechia, Poland, Germany
ImmuneMed, Inc.

Not yet recruiting

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Moderate to Severe Rheumatoid Arthritis

Netherlands
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
Amgen

Terminated

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (ROCkIES)

Moderate to Severe Rheumatoid Arthritis

United States, Canada, Puerto Rico
AbbVie (prior sponsor, Abbott)
University Health Network, Toronto

Completed

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)

Moderate-to-severe Rheumatoid Arthritis
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

Moderate to Severe Active Rheumatoid Arthritis

China
Synta Pharmaceuticals Corp.

Completed

A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

Active, Moderate to Severe Rheumatoid Arthritis

Netherlands
Shanghai Henlius Biotech

Completed

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Moderately to Severely Active Rheumatoid Arthritis

China
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Moderate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's Disease

United States
Biosplice Therapeutics, Inc.

Completed

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Moderate to Severe Osteoarthritis

United States
Zimmer, GmbH

Active, not recruiting

Zimmer POLAR Persona - TKA (EMEA Study)

Osteoarthritis | Rheumatoid Arthritis | Traumatic Arthritis | Polyarthritis | Severe Knee Pain | Severe Knee Disability

France, Spain, United Kingdom, Austria, Germany, Netherlands
Encore Medical, L.P.

Completed

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use (STAR 2 PAS)

Osteoarthritis | Rheumatoid Arthritis | Post Traumatic Arthritis | Primary Arthrosis

United States
Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation

Completed

Upper Facial Remodeling With Perlane-L and Dysport (DPL-2010)

Mild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital Rhytids

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

Moderate-severe Glabellar Lines
AlloSource

Completed

Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft

Post-traumatic; Arthrosis | Degenerative Osteoarthritis | Rheumatoid Arthritis & Other Inflammatory Polyarthropathies | Rheumatoid Arthritis of Subtalar Joint

United States
Zimmer Biomet

Completed

Sidus Stem-Free Shoulder IDE Study

Osteoarthritis | Rheumatoid Arthritis | Posttraumatic Arthrosis

United States, Canada
Aesculap AG

Completed

Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis

Osteoarthritis | Rheumatoid Arthritis | Post-traumatic; Arthrosis

Germany
Aqpha Medical B.V.

Not yet recruiting

Safety and Performance of PTMC Dermal Filler

Moderate to Severe Nasolabial Fold
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Allergan

Completed

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Moderate to Severe Nasolabial Folds

Germany, Netherlands
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Anti-age Food Supplement

Moderate-severe Skin Aging/Photoaging
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
University Hospital, Bordeaux

Completed

Study of the Articular Microbiota in Rheumatoid Arthritis. (MICROPORE)

Rheumatoid Arthritis | Arthrosis | Synovial Disorder
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Croma-Pharma GmbH

Completed

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Moderate to Severe Nasolabial Folds

Austria
Allergan

Completed

A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Moderate to Severe Nasolabial Folds

United States
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
Merz North America, Inc.

Completed

Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit

Moderate to Severe Midface Volume Deficit

Canada
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Merz Aesthetics GmbH
Merz Pharmaceuticals GmbH

Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States, Germany
Croma-Pharma GmbH

Active, not recruiting

Saypha® VOLUME Lidocaine for Midface Augmentation (VOLIDO)

Moderate to Severe Midface Volume Deficit

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Allergan

Completed

JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines

Patients With Moderate to Severe Perioral Lines

United States
AbbVie

Completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Rheumatoid Arthritis (RA)

Brazil, China, Korea, Republic of

3

Subscribe